← Eichor
Condition: Melanoma Stage Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Melanoma Stage

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT02830724SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
Phase 3 · 3 location(s) · Hildur Helgadottir · NCT06794775A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Phase 1 · 40 location(s) · Pfizer · NCT05355701A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05837767A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-0
Phase 2 · 38 location(s) · Merck Sharp & Dohme LLC · NCT06961006A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Mela
Phase 1 · 4 location(s) · Alpha-9 Oncology USA Inc. · NCT07076550A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 47 location(s) · Bristol-Myers Squibb · NCT04895709A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
Phase 1/Phase 2 · 9 location(s) · NuCana plc · NCT03829254Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
Phase 2 · 1 location(s) · University of California, Irvine · NCT06771544A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma
NA · 20 location(s) · Uppsala University · NCT03116412Versatile Ampification Single-Molecule Detection in Liquid Biopsy
Phase N/A · 1 location(s) · Regina Elena Cancer Institute · NCT05940311Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Phase 2 · 3 location(s) · Psyence Australia Pty Ltd · NCT07072728A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Phase 1 · 2 location(s) · Hefei TG ImmunoPharma Co., Ltd. · NCT05746897Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05026983RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
EARLY_Phase 1 · 1 location(s) · Yana Najjar · NCT06216938A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
Phase 1 · 7 location(s) · Shanghai Henlius Biotech · NCT07518043A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced So
Phase 1 · 83 location(s) · Pfizer · NCT05538130OH2 Injection in Melanoma
Phase 3 · 30 location(s) · Binhui Biopharmaceutical Co., Ltd. · NCT05868707Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05155033A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1 · 10 location(s) · Compass Therapeutics · NCT06150664Study of GV20-0251 in Participants With Solid Tumor Malignancies
Phase 1/Phase 2 · 3 location(s) · GV20 Therapeutics · NCT07070518Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Phase 2 · 2 location(s) · Brigham and Women's Hospital · NCT04899908MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Phase 1/Phase 2 · 13 location(s) · Perspective Therapeutics · NCT05655312Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Shandong Boan Biotechnology Co., Ltd · NCT06596915Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Phase 2 · 3 location(s) · Abramson Cancer Center at Penn Medicine · NCT03646617Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to
Phase 3 · 270 location(s) · NRG Oncology · NCT06500455Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Phase 1/Phase 2 · 17 location(s) · Aminex Therapeutics, Inc. · NCT07287917A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
Phase 1/Phase 2 · 1 location(s) · University of Louisville · NCT01638676A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multi
Phase 1 · 69 location(s) · Shanghai Henlius Biotech · NCT07160335
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.